Antibody therapies for multiple myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am Soc Clin Oncol Educ Book. 2014;199–203.
   PubMedGoogle Scholar
• van de Donk NW, Sonneveld P. Diagnosis and risk stratification in multiple myeloma. Hematol Oncol Clin North Am. 2014;28:791–813.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127:2955–2962.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–2448.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–1848.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103:2088–2096.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
   PubMed Web of Science ®Google Scholar
• Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103:2079–2087.
   PubMed Web of Science ®Google Scholar
• Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130:974–981.
   PubMed Web of Science ®Google Scholar
• Lonial S, San-Miguel JF, Martínez-Lopez J, et al. Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed Multiple Myeloma (MMY1001): an open-label, phase 1b study. Blood. 2017;130:1869.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with Relapsed or Refractory Multiple Myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study candor (NCT03158688). Blood. 2019;134:LBA–1.
   Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–528.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Cavo M, Bladé J, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone. Blood. 2019;134:859.
   Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104–2115.
   PubMed Web of Science ®Google Scholar
• Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019;185:492–502.
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Melear JM, Faber E, et al. Daratumumab (DARA) maintenance therapy improves depth of response and results in durable Progression-Free Survival (PFS) following dara plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) induction therapy in Multiple Myeloma (MM): update of the lyra study. Blood. 2019;134:863.
   Google Scholar
• Voorhees P, Rodriguez C, Reeves B. Efficacy and updated safety analysis of a safety run-in cohort from Griffin, a phase 2 randomized study of daratumumab (Dara), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara-Vrd) vs. Vrd in patients (Pts) with newly diagnosed (ND) multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood. 2018;132:151.
   Google Scholar
• Voorhees PM, Kaufman JL, Laubach JP, et al. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin study update. Blood. 2019;134:691.
   Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.
   Web of Science ®Google Scholar
• Jakubowiak A, Chari A, Lonial S, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol. 2017;35:8000.
   Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, Measurable Residual Disease (MRD)-based Dara-Krd consolidation in patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood. 2019;134:860.
   PubMed Web of Science ®Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129:3294–3303.
   PubMed Web of Science ®Google Scholar
• Richardson P, Attal M, Rajkumar S, et al. A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2019;37(suppl):abstr 8004.
   Google Scholar
• Krishnan AY, Patel KK, Hari P, et al. Preliminary results from a phase 1b study of TAK-079, an investigational anti-CD38 monoclonal Antibody (mAb) in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2019;134:140.
   Web of Science ®Google Scholar
• Raab MS, Chatterjee M, Goldschmidt H, et al. MOR202 with low-dose Dexamethasone (Dex) or pomalidomide/dex or lenalidomide/dex in Relapsed or Refractory Multiple Myeloma (RRMM): primary analysis of a phase I/IIa, multicenter, dose-escalation study. Blood. 2019;132:153.
   Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124:4032–4043.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Terpos E, Dimopoulos MA. The extended 4-year follow-up results of the ELOQUENT-2 trial. Oncotarget. 2019;10:82–83.
   PubMedGoogle Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–1822.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pegourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127:2833–2840.
   PubMed Web of Science ®Google Scholar
• Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192:129–135.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–694.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, et al. Anti-BCMA antibodies in the future management of multiple myeloma. Expert Rev Anticancer Ther. 2019;19:319–326.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727–738.
   PubMed Web of Science ®Google Scholar
• Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–3138.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Popat R, Trudel S, et al. First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell Maturation Antigen (BCMA) in patients with relapsed/refractory Multiple Myeloma (MM): results from study BMA117159 part 1 dose escalation. Blood. 2016;128:1148.
   Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37.
   PubMed Web of Science ®Google Scholar
• Kinneer K, Meekin J, Varkey R, et al. Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma. Blood. 2017;130:3153.
   Web of Science ®Google Scholar
• Kleber M, Ntanasis-Stathopoulos I, Dimopoulos MA, et al. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care? Expert Rev Hematol. 2019;12:651–663.
   PubMed Web of Science ®Google Scholar
• Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12:1221–1228.
   PubMed Web of Science ®Google Scholar
• Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8:7.
   PubMed Web of Science ®Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19:370–381.
   PubMed Web of Science ®Google Scholar
• Terpos E, Willenbacher W, Shimizu K, et al. Progression-free survival subset analysis - denosumab vs zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomized controlled phase 3 study. Blood. 2018;132:1969.
   Web of Science ®Google Scholar
• Cheng BC, Chen YC. Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density. Clin Rheumatol. 2017;36:929–932.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829–1835.
   PubMed Web of Science ®Google Scholar
• Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471–1479.
   PubMed Web of Science ®Google Scholar
• Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534–1539.
   PubMed Web of Science ®Google Scholar
• Paiva B, Azpilikueta A, Puig N, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29:2110–2113.
   PubMed Web of Science ®Google Scholar
• Chen D, Tang P, Liu L, et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway. Cell Cycle. 2018;17:858–867.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Orlowski RZ, Siegel DSD, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): final efficacy and safety analysis. J Clin Oncol. 2016;34:8010.
   Web of Science ®Google Scholar
• Mateos MV, Orlowski RZ, Ocio EM, et al. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. 2019;186:e117-e121.
   Web of Science ®Google Scholar
• Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;130:1189–1197.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Schjesvold F, Oriol A, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6:e448-e458.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019:e459-e469.
   Web of Science ®Google Scholar
• Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:2278.
   PubMed Web of Science ®Google Scholar
• Topp MS, Duell J, Zugmaier G, et al. Treatment with AMG 420, an anti-B-cell Maturation Antigen (BCMA) Bispecific T-cell Engager (BiTE®) antibody construct, induces Minimal Residual Disease (MRD) negative complete responses in relapsed and/or refractory (R/R) Multiple Myeloma (MM) patients: results of a First-In-Human (FIH) phase I dose escalation study. Blood. 2018;132:1010.
   Web of Science ®Google Scholar
• Topp MS, Duell J, Zugmaier G, et al. Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study. J Clin Oncol. 2019;37:8007.
   Web of Science ®Google Scholar
• Lesokhin AM, Raje N, Gasparetto CJ, et al. A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen/CD3 bispecific antibody, in patients with relapsed/refractory advanced multiple myeloma. Blood. 2018;132:3229.
   Web of Science ®Google Scholar
• Costa LJ, Wong SW, Bermúdez A, et al. First clinical study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134:143.
   Google Scholar
• Nass SJ, Rothenberg ML, Pentz R, et al. Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018;15:777–786.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, van de Donk N, Zweegman S, et al. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78:19–37.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133:660–675.
   PubMed Web of Science ®Google Scholar
• Ocana A, Ethier JL, Diez-Gonzalez L, et al. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget. 2015;6:39538–39549.
   PubMed Web of Science ®Google Scholar
• Chia S, Low JL, Zhang X, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017;8:435.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401–2409.
   PubMed Web of Science ®Google Scholar
• Chung C. Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: an evolving therapeutic strategy. Pharmacotherapy. 2017;37:129–143.
   PubMed Web of Science ®Google Scholar
• Oostvogels R, Jak M, Raymakers R, et al. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Br J Haematol. 2018;183:60–67.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Joseph NS, Kaufman JL, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer. 2019;125:2991–3000.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, et al. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018;131:464–467.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.
   PubMed Web of Science ®Google Scholar
• Manni S, Carrino M, Semenzato G, et al. Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance. Int J Mol Sci. 2018;19:1512.
   PubMed Web of Science ®Google Scholar
• Guang MHZ, McCann A, Bianchi G, et al. Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’. Leuk Lymphoma. 2018;59:542–561.
   PubMed Web of Science ®Google Scholar
• Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–3051.
   PubMed Web of Science ®Google Scholar